Market Overview

UBS 'Looking Elsewhere,' Says To Sell Regeneron

Share:
Related REGN
Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'
Benzinga's Top Upgrades, Downgrades For April 9, 2018
Oakmark Equity And Income Fund: Q1 2018 (Seeking Alpha)
Related SNY
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'
MannKind: Experts In Pulling Numbers From Orifices (Seeking Alpha)

In a report published Thursday, UBS analyst Matthew Roden downgraded the rating on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) from Neutral to Sell, citing the surge in shares, while maintaining a price target of $500.

Regeneron's shares have been the best performer in the large cap biotech segment this year. The outperformance has been driven by the company's opportunities with Eylea, Praluent and pipeline programs like dupilumab. The markets have also appreciated the strategic value and the benefits of Regeneron's collaboration with Sanofi SA (NYSE: SNY).

Analyst Matthew Roden believes that the appreciation in Regeneron shares was "disconnected from peers."

"We appreciate the long term value-creating potential of Regeneron's business, and we are supportive of management and the business model. However, we also see the current price of REGN shares as a less attractive entry point relative to peers," Roden added.

In the report UBS noted, "Praluent is likely to be approved with a label that is broader than the FDA Advisory Committee recommended. We expect it to be similar to the positive CHMP opinion for Repatha. However, we think most REGN and AMGN bulls expect a broader label already, suggesting limited upside on the event."

Regeneron's long-term outlook looks favorable with Eylea expected to grow with geographic and label expansion. The company's key pipeline programs alirocumab, sarilumab and dupilumab could be potential blockbusters or may face competition from other similar drugs.

"We wait for a more attractive entry," the report stated.

Latest Ratings for REGN

DateFirmActionFromTo
Apr 2018Raymond JamesDowngradesOutperformMarket Perform
Feb 2018Canaccord GenuityDowngradesBuyHold
Feb 2018BMO CapitalMaintainsMarket PerformMarket Perform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: UBSAnalyst Color Downgrades Analyst Ratings

 

Related Articles (REGN + SNY)

View Comments and Join the Discussion!